Barclays’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-30,260
| Closed | -$48.1K | – | 5432 |
|
|
2024
Q1 | $48.1K | Sell |
30,260
-60,932
| -67% | -$90.4K | ﹤0.01% | 4621 |
|
|
2023
Q4 | $78.3K | Buy |
91,192
+52,331
| +135% | +$46K | ﹤0.01% | 4691 |
|
|
2023
Q3 | $41.6K | Sell |
38,861
-1,529
| -4% | -$3.16K | ﹤0.01% | 3945 |
|
|
2023
Q2 | $105K | Sell |
40,390
-3,687
| -8% | -$13.2K | ﹤0.01% | 3537 |
|
|
2023
Q1 | $180K | Sell |
44,077
-25,827
| -37% | -$119K | ﹤0.01% | 3856 |
|
|
2022
Q4 | $351K | Buy |
69,904
+26,009
| +59% | +$163K | ﹤0.01% | 3526 |
|
|
2022
Q3 | $575K | Buy |
43,895
+18,459
| +73% | +$280K | ﹤0.01% | 2616 |
|
|
2022
Q2 | $326K | Buy |
25,436
+6,065
| +31% | +$84K | ﹤0.01% | 3144 |
|
|
2022
Q1 | $295K | Sell |
19,371
-36,389
| -65% | -$568K | ﹤0.01% | 3209 |
|
|
2021
Q4 | $987K | Buy |
55,760
+23,499
| +73% | +$451K | ﹤0.01% | 2843 |
|
|
2021
Q3 | $679K | Buy |
32,261
+26,059
| +420% | +$574K | ﹤0.01% | 3023 |
|
|
2021
Q2 | $123K | Sell |
6,202
-20,367
| -77% | -$477K | ﹤0.01% | 3766 |
|
|
2021
Q1 | $773K | Buy |
26,569
+10,331
| +64% | +$289K | ﹤0.01% | 2928 |
|
|
2020
Q4 | $492K | Sell |
16,238
-9,158
| -36% | -$200K | ﹤0.01% | 3239 |
|
|
2020
Q3 | $404K | Buy |
25,396
+2,566
| +11% | +$46.8K | ﹤0.01% | 3387 |
|
|
2020
Q2 | $450K | Buy |
22,830
+449
| +2% | +$8.58K | ﹤0.01% | 3421 |
|
|
2020
Q1 | $276K | Sell |
22,381
-20,933
| -48% | -$342K | ﹤0.01% | 4056 |
|
|
2019
Q4 | $800K | Buy |
43,314
+14,398
| +50% | +$210K | ﹤0.01% | 3870 |
|
|
2019
Q3 | $401K | Sell |
28,916
-377
| -1% | -$5.66K | ﹤0.01% | 4420 |
|
|
2019
Q2 | $428K | Buy |
+29,293
| New | +$429K | ﹤0.01% | 4463 |
|
Barclays's NGM Position: Q2 2024 in Review
Barclays sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 30,260 shares — an estimated $48.1K sold.
Barclays first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $987K in Q4 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Barclays reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Barclays sold 30,260 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $48.1K.
- Barclays first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Barclays's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $987K in Q4 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.